Zacks Investment Research on MSN10d
Pfizer's Q4 Earnings Beat Estimates, Non-Covid Drugs Drive SalesPfizer PFE reported fourth-quarter 2024 adjusted earnings per share of 63 cents, which beat the Zacks Consensus Estimate of ...
Septerna has a market cap of $750mn and $130mn in cash and ST investments. Discover SEPN's groundbreaking drug discovery ...
This leap enabled systems like ChatGPT and Llama to dominate the AI landscape. However, the rise of AI model aggregators is now bringing long-overdue attention to the broader ecosystem, streamlining ...
Nebraska will receive $62,688.71. Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine medication. The company also paid some ...
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its migraine medicine Nurtec ODT … ...
Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023. Known as Vydura in Europe, Nurtec ODT ...
Biohaven knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to health care providers to induce prescriptions of Biohaven’s drug ...
Nurtec ODT, also known as Rimegepant, was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021. The drug was promoted by ...
Biohaven Pharmaceutical Holding, from March 2020 through September 2022, selected certain healthcare providers to be part of a group to promote its drug Nurtec ODT, a migraine treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback